Novartis submits COPD combination inhaler in Japan

Following its filing in Europe in October, Novartis ($NVS) has submitted the once-daily inhaled combination drug QVA149 for approval in Japan for the maintenance treatment of COPD in adults. QVA149 combines fixed doses of two long-acting inhaled bronchodilators, glycopyrronium bromide (licensed from Vectura and its co-development partner Sosei), and indacaterol maleate, in Novartis' Breezhaler single-dose dry powder inhaler. The product has now been launched in Germany and the U.K., and approved in Canada and Australia, and submission in the U.S. is planned for 2014. Press release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…